Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells
- 319 Downloads
Various combinations of drugs may be effective in the treatment of different types of cancer. Previously, we have shown that combinations of the histone deacetylase inhibitor panobinostat and the topoisomerase inhibitors topotecan or etoposide act synergistically, but the underlying mode of action has remained unknown. Here, we aimed at uncovering the mechanisms underlying this synergism.
The effects of (combinations of) panobinostat and topotecan or etoposide on cervical cancer-derived HeLa and SiHa cells were assessed using morphological evaluations, scratch wound healing assays, cell cycle analyses, AO/EB staining assays, Annexin V/PI staining assays, reactive oxygen species (ROS) and mitochondrial membrane potential measurements and Western blotting.
We found that combinations of panobinostat and the topoisomerase inhibitors topotecan or etoposide synergistically enhanced the induction of apoptosis in both HeLa and SiHa cells. This enhanced apoptosis induction was found to be mediated through increased ROS production and induction of the mitochondrial apoptotic pathway. We also found that the combination treatment resulted in inhibition of the PI3K/AKT and NF-κB pro-survival pathways and in activation of the ERK pathway, which is associated with intrinsic apoptosis.
From our data we conclude that combinations of panobinostat and the topoisomerase inhibitors topotecan or etoposide provoke strong cell death responses in cervical cancer-derived cells via induction of the intrinsic apoptotic pathway. Since this drug combination may potentially be effective in the treatment of cervical cancer, further preclinical investigations are warranted.
KeywordsCombination therapy Panobinostat Topoisomerase inhibitors ROS Apoptosis AKT/NF-κB ERK
The authors wish to thank the University of Delhi, India, for providing funds in the form of a DUR&D grant and a UGC-SAP grant and UGC, New Delhi, India, for providing a fellowship to LW. We also wish to thank Mr. Prateek Arora for helping in FCM.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 1.Y. Sun, Z. Sheng, C. Ma, K. Tang, R. Zhu, Z. Wu, R. Shen, J. Feng, D. Wu, D. Huang, D. Huang, J. Fei, Q. Liu, Z. Cao, Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. Nat Commun 6, 8481 (2015). https://doi.org/10.1038/ncomms9481 CrossRefPubMedCentralPubMedGoogle Scholar
- 8.K. Ozaki, F. Kishikawa, M. Tanaka, T. Sakamoto, S. Tanimura, M. Kohno, Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drug. Cancer Sci 99, 376–384 (2008). https://doi.org/10.1111/j.1349-7006.2007.00669.x CrossRefPubMedGoogle Scholar
- 10.R.S. Hotchkiss, A. Strasser, J.E. McDunn, P.E. Swanson, Cell Death. N Engl J Med 361, 1570–1583 (2009). https://doi.org/10.1056/NEJMra0901217
- 11.J.F. Kerr, C.M. Winterford, B.V. Harmon, Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013–2026 (1994). https://doi.org/10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J CrossRefPubMedGoogle Scholar
- 14.D.R. Budman, A. Calabro, L. Rosen, M. Lesser, Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system. Anti-Cancer Drugs 23, 272–279 (2012). https://doi.org/10.1097/CAD.0b013e32834ebda4 CrossRefPubMedCentralPubMedGoogle Scholar
- 16.S. Venkannagari, W. Fiskus, K. Peth, P. Atadja, M. Hidalgo, A. Maitra, K.N. Bhalla, Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget 3, 1416–1427 (2012). https://doi.org/10.18632/oncotarget.724 CrossRefPubMedCentralPubMedGoogle Scholar
- 17.G. Wang, H. Edwards, J.T. Caldwell, S.A. Buck, W.Y. Qing, J.W. Taub, Y. Ge, Z. Wang, Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One 8, e76662 (2013). https://doi.org/10.1371/journal.pone.0076662 CrossRefPubMedCentralPubMedGoogle Scholar
- 18.F. Bruzzese, M. Rocco, S. Castelli, E. Di Gennaro, A. Desideri, A. Budillon, Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 8, 3075–3087 (2009). https://doi.org/10.1158/1535-7163.MCT-09-0254 CrossRefPubMedGoogle Scholar
- 21.O. Sordet, Q.A. Khan, I. Plo, P. Pourquier, Y. Urasaki, A. Yoshida, S. Antony, G. Kohlhagen, E. Solary, M. Saparbaev, J. Laval, Y. Pommier, Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J Biol Chem 279, 50499–50504 (2004). https://doi.org/10.1074/jbc.M410277200 CrossRefPubMedGoogle Scholar
- 22.M.D. Brand, C. Affourtit, T.C. Esteves, K. Green, A.J. Lambert, S. Miwa, J.L. Pakay, N. Parker, Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 37(6), 755–767 (2004). https://doi.org/10.1016/j.freeradbiomed.2004.05.034 CrossRefPubMedGoogle Scholar
- 28.G. Song, G. Ouyang, S. Bao, The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9, 59–71 (2005). https://doi.org/10.1111/j.1582-4934.2005.tb00337.x CrossRefPubMedGoogle Scholar
- 30.F. Chang, J.T. Lee, P.M. Navolanic, L.S. Steelman, J.G. Shelton, W.L. Blalock, R.A. Franklin, J.A. McCubrey, Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 17, 590–603 (2003). https://doi.org/10.1038/sj.leu.2402824 CrossRefPubMedGoogle Scholar
- 33.C. Yu, B.B. Friday, J.P. Lai, A. McCollum, P. Atadja, L.R. Roberts, A.A. Adjei, Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 13, 1140–1148 (2007). https://doi.org/10.1158/1078-0432.CCR-06-1751 CrossRefPubMedGoogle Scholar
- 36.J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C. Evangelisti, A.M. Martelli, R.A. Franklin, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773, 1263–1284 (2007). https://doi.org/10.1016/j.bbamcr.2006.10.001 CrossRefPubMedGoogle Scholar
- 37.M.J. Chuang, S.T. Wu, S.H. Tang, X.M. Lai, H.C. Lai, K.H. Hsu, K.H. Sun, G.H. Sun, S.Y. Chang, D.S. Yu, P.W. Hsiao, S.M. Huang, T.L. Cha, The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PLoS One 8, e73401 (2013). https://doi.org/10.1371/journal.pone.0073401 CrossRefPubMedCentralPubMedGoogle Scholar